• AQUA Cultured Foods

  Participated · Seed · Apr 2023

  Aqua Cultured Foods develops whole‑muscle seafood alternatives — calamari, shrimp, scallops, tuna and whitefish filets — plus minced fillings for dumplings, ravioli and sushi. The company uses proprietary mycoprotein (fungi) fermentation processes with no animal inputs or genetic modification and says its products are optimized to be consumed raw with textures close to conventional seafood. Aqua is Chicago‑based and recently acquired a 5,000‑square‑foot food‑grade pilot facility and expects to begin manufacturing first products (tuna, scallops and ground shrimp) by early summer. The team says a 450‑square‑foot grow space could produce between 5,000 and 10,000 pounds of product, supporting decentralized manufacturing for future market expansion. Planned uses of the new funding include hiring, expanding restaurant and foodservice introductions, and running chef pop‑ups to gauge demand. Financially, the company announced a $5.5M seed round and has raised just over $8M to date. Aqua Cultured Foods makes animal-free seafood analogs using a microbial fermentation process and a proprietary strain of fungi. The company produces a “whole-grown” protein it says requires no extra processing or genetic modification, yielding a more robust nutritional profile than many plant-based seafood options. Its inherently flavorless base can be fine-tuned late in the growth process to create textures and flavors for products such as tuna, whitefish, calamari, shrimp, and scallops. Founded in 2020 and based in Chicago, Aqua Cultured Foods raised $2.1 million in pre-seed funding to support rapid growth. The startup is targeting 2022 for commercial releases, initially via limited-time foodservice offerings with retail planned later, and reports early sales interest and strategic partnerships. The new capital will be used to build the team and accelerate R&D to iterate on texture, shape, nutritional value, and flavor to bring products closer to animal-derived versions.

• BIOHM

  Participated · Equity · Jan 2023

  Biohm is a Cleveland, OH-based microbiome company that leverages microbiome data to create products and ingredients intended to improve individual health. Its product lineup includes the BIOHM FX probiotic supplement designed to reduce digestive plaque, additional probiotic and prebiotic supplements, and a personalized Gut Test. The company raised $7.5M in equity financing to support growth. Biohm plans to use the funds to fast-track development of A.I. technology and targeted, data-driven microbiome formulations. The company is led by CEO Afif Ghannoum and President Sam Schatz. Biohm Health is a microbiome company that applies a proprietary dual-action technology to neutralize harmful bacteria and fungi and deliver a probiotic designed to break down digestive plaque while maintaining overall microbiome balance. The company sells probiotics and other gut-health products and offers The BIOHM Gut Report, a test that identifies and measures gut bacteria and fungi and provides personalized, actionable wellness recommendations including nutritional advice. The business is led by CEO Afif Ghannoum and was founded by Afif Ghannoum and Dr. Mahmoud Ghannoum following their discovery that bad bacteria and bad fungus collaborate to create digestive imbalance. Biohm is based in Cleveland, OH. In December 2017 the company raised funding from Vanterra Capital; the terms of the investment were not disclosed. As part of the deal, Vanterra will join BIOHM's board alongside the founders.

No current team members are available.